BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Recommendation of “Hold” by Analysts

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has been given a consensus rating of “Hold” by the four brokerages that are covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $37.50.

BTAI has been the subject of several recent analyst reports. Zacks Research lowered shares of BioXcel Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Wednesday, January 28th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Wednesday, January 21st.

BioXcel Therapeutics Stock Up 9.5%

Shares of BioXcel Therapeutics stock opened at $1.50 on Monday. BioXcel Therapeutics has a 52 week low of $1.17 and a 52 week high of $8.08. The business has a 50 day moving average price of $1.82 and a 200-day moving average price of $2.52. The company has a market cap of $32.80 million, a PE ratio of -0.15 and a beta of 0.22.

BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($2.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.64). The company had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. As a group, research analysts anticipate that BioXcel Therapeutics will post -24.39 EPS for the current year.

Institutional Trading of BioXcel Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Diversify Wealth Management LLC purchased a new position in BioXcel Therapeutics in the second quarter worth $27,000. XTX Topco Ltd purchased a new position in shares of BioXcel Therapeutics in the 2nd quarter worth about $42,000. Goldman Sachs Group Inc. purchased a new position in shares of BioXcel Therapeutics in the 1st quarter worth about $50,000. Geode Capital Management LLC grew its position in BioXcel Therapeutics by 27.7% during the second quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock valued at $51,000 after buying an additional 6,120 shares during the period. Finally, Foundations Investment Advisors LLC purchased a new stake in BioXcel Therapeutics during the third quarter worth about $76,000. 30.68% of the stock is owned by hedge funds and other institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.